NCT04809025Recruiting
Comparation of Endoscopic Biopsy and Postoperative Specimen for the Molecular Diagnosis of Gastric Cancer
Source: ClinicalTrials.gov · Last updated 29 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study aims to test the hypothesis that the diagnosis for histological type, histological grade, LAUREN type, HER-2 expression, MSI/dMMR status, and EBV status in gastric cancer is at least as reliable when performed on endoscopic biopsy specimens as on surgical resection specimens.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 510 (estimated)
- First submitted
- 19 Mar 2021
- Start date
- 24 May 2021
- Primary completion date
- 1 Sept 2026
- Lead sponsor
- Fudan University
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT04809025
What you commit to
- Study type: Observational
- Planned participants: 510
- From 24 May 2021 to the primary completion date, 1 Sept 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients received any anticancer drugs, biotherapy, radiotherapy or immunotherapy within 4 weeks before or after enrollment.
Other illness
- Patients with gastric cancer who can not undergo tumor resection
- Suffering from other serious diseases, including cardiovascular, respiratory, kidney, or liver disease, complicated by poorly controlled hypertension, diabetes, mental disorders or diseases.
- Patients after organ transplantation, long-term need to take immunosuppressants, autoimmune diseases.
Other
- Female in pregnancy or lactation.
- Patients with poor compliance or considered to be poor compliance.
Who the study is looking for
- Lower age limit of research subjects 18 years old and upper age limit of 75 years old.
- Histologically proven primary gastric adenocarcinoma (Diagnostic biopsies must be collected within 12 months prior to enrollment).
- Written informed consent from the patient.
- Patients planned for radical R0 gastrectomy.
Age in the registry: 18 years to 75 years · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fudan University Shanghai Cancer Center Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.